161 related articles for article (PubMed ID: 30448568)
1. The combined utility of myeloperoxidase (MPO) and paraoxonase 1 (PON1) as two important HDL-associated enzymes in coronary artery disease: Which has a stronger predictive role?
Variji A; Shokri Y; Fallahpour S; Zargari M; Bagheri B; Abediankenari S; Alizadeh A; Mahrooz A
Atherosclerosis; 2019 Jan; 280():7-13. PubMed ID: 30448568
[TBL] [Abstract][Full Text] [Related]
2. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.
Haraguchi Y; Toh R; Hasokawa M; Nakajima H; Honjo T; Otsui K; Mori K; Miyamoto-Sasaki M; Shinohara M; Nishimura K; Ishida T; Hirata K
Atherosclerosis; 2014 Jun; 234(2):288-94. PubMed ID: 24704632
[TBL] [Abstract][Full Text] [Related]
3. Improved risk assessment of coronary artery disease by substituting paraoxonase 1 activity for HDL-C: Novel cardiometabolic biomarkers based on HDL functionality.
Mahrooz A; Shokri Y; Variji A; Zargari M; Alizadeh A; Mehtarian E
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1166-1176. PubMed ID: 33579580
[TBL] [Abstract][Full Text] [Related]
4. Can HDL cholesterol be replaced by paraoxonase 1 activity in the prediction of severe coronary artery disease in patients with type 2 diabetes?
Mahrooz A; Khosravi-Asrami OF; Alizadeh A; Mohmmadi N; Bagheri A; Kashi Z; Bahar A; Nosrati M; Mackness M
Nutr Metab Cardiovasc Dis; 2023 Aug; 33(8):1599-1607. PubMed ID: 37344284
[TBL] [Abstract][Full Text] [Related]
5. Association between HDL particles size and myeloperoxidase/ paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome.
Emami Razavi A; Basati G; Varshosaz J; Abdi S
Acta Med Iran; 2013 Jul; 51(6):365-71. PubMed ID: 23852840
[TBL] [Abstract][Full Text] [Related]
6. Low serum paraoxonase1 activity levels predict coronary artery disease severity.
Sun T; Hu J; Yin Z; Xu Z; Zhang L; Fan L; Zhuo Y; Wang C
Oncotarget; 2017 Mar; 8(12):19443-19454. PubMed ID: 28038449
[TBL] [Abstract][Full Text] [Related]
7. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease.
Yunoki K; Naruko T; Inaba M; Inoue T; Nakagawa M; Sugioka K; Ohsawa M; Iwasa Y; Komatsu R; Itoh A; Haze K; Yoshiyama M; Becker AE; Ueda M
Atherosclerosis; 2013 Dec; 231(2):308-14. PubMed ID: 24267244
[TBL] [Abstract][Full Text] [Related]
8. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease.
Göçmen AY; Gümüşlü S; Semiz E
Clin Cardiol; 2004 Jul; 27(7):426-30. PubMed ID: 15298047
[TBL] [Abstract][Full Text] [Related]
9. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease.
Ding J; Chen Q; Zhuang X; Feng Z; Xu L; Chen F
Med Sci Monit; 2014 Nov; 20():2421-9. PubMed ID: 25420483
[TBL] [Abstract][Full Text] [Related]
10. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease.
Vaisi-Raygani A; Ghaneialvar H; Rahimi Z; Tavilani H; Pourmotabbed T; Shakiba E; Vaisi-Raygani A; Kiani A; Aminian M; Alibakhshi R; Bartels C
Mol Biol Rep; 2011 Nov; 38(8):5421-8. PubMed ID: 21465165
[TBL] [Abstract][Full Text] [Related]
11. Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus.
Shen Y; Ding FH; Sun JT; Pu LJ; Zhang RY; Zhang Q; Chen QJ; Shen WF; Lu L
Cardiovasc Diabetol; 2015 May; 14():52. PubMed ID: 25964115
[TBL] [Abstract][Full Text] [Related]
12. Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers in overweight patients with newly diagnosed untreated hyperlipidaemia.
Szentpéteri A; Zsíros N; Varga VE; Lőrincz H; Katkó M; Seres I; Fülöp P; Paragh G; Harangi M
Vasa; 2017 Aug; 46(5):370-376. PubMed ID: 28602123
[TBL] [Abstract][Full Text] [Related]
13. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
Jornayvaz FR; Brulhart-Meynet MC; James RW
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):613-9. PubMed ID: 19201174
[TBL] [Abstract][Full Text] [Related]
14. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes.
Ndrepepa G; Braun S; Mehilli J; von Beckerath N; Schömig A; Kastrati A
Eur J Clin Invest; 2008 Feb; 38(2):90-6. PubMed ID: 18226042
[TBL] [Abstract][Full Text] [Related]
15. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus.
Singh S; Venketesh S; Verma JS; Verma M; Lellamma CO; Goel RC
Indian J Med Res; 2007 Jun; 125(6):783-7. PubMed ID: 17704557
[TBL] [Abstract][Full Text] [Related]
16. Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications.
Zsíros N; Koncsos P; Lőrincz H; Seres I; Katkó M; Szentpéteri A; Varga VE; Fülöp P; Paragh G; Harangi M
Clin Biochem; 2016 Aug; 49(12):862-7. PubMed ID: 27129797
[TBL] [Abstract][Full Text] [Related]
17. Novel serum paraoxonase activity assays are associated with coronary artery disease.
Martinelli N; Girelli D; Olivieri O; Guarini P; Bassi A; Trabetti E; Friso S; Pizzolo F; Bozzini C; Tenuti I; Annarumma L; Schiavon R; Franco Pignatti P; Corrocher R
Clin Chem Lab Med; 2009; 47(4):432-40. PubMed ID: 19275503
[TBL] [Abstract][Full Text] [Related]
18. Myeloperoxidase-induced modification of HDL by isolevuglandins inhibits paraoxonase-1 activity.
Aggarwal G; May-Zhang LS; Yermalitsky V; Dikalov S; Voynov MA; Amarnath V; Kon V; Linton MF; Vickers KC; Davies SS
J Biol Chem; 2021 Sep; 297(3):101019. PubMed ID: 34331945
[TBL] [Abstract][Full Text] [Related]
19. Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study.
Khine HW; Teiber JF; Haley RW; Khera A; Ayers CR; Rohatgi A
Atherosclerosis; 2017 Aug; 263():156-162. PubMed ID: 28645072
[TBL] [Abstract][Full Text] [Related]
20. Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease.
Wang G; Mathew AV; Yu H; Li L; He L; Gao W; Liu X; Guo Y; Byun J; Zhang J; Chen YE; Pennathur S
PLoS One; 2018; 13(3):e0193782. PubMed ID: 29505607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
